Everolimus for Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Gastrointestinal (GI) Tract: Efficacy and Safety from a RADIANT-4 Subgroup Analysis
#1495
Introduction: Everolimus (EVE) demonstrated progression-free survival (PFS) benefit of 7.1 months compared to placebo in the phase 3 RADIANT-4 study in patients (pts) with advanced, well-differentiated, progressive, nonfunctional NET.
Aim(s): To evaluate the efficacy and safety of EVE in GI NET subset of RADIANT-4.
Materials and methods: In RADIANT-4, pts were randomized (2:1) to EVE (10 mg/d) or PBO. The present analysis included pts with GI NET (stomach, colon, rectum, appendix, caecum, ileum, duodenum, jejunum, or small intestine).
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: Singh S
Authors: Singh S, Carnaghi C, Buzzoni R, Raderer M, Lahner H,
Keywords: Everolimus, progression-free survival, gastrointestinal NET,
To read the full abstract, please log into your ENETS Member account.